CIBC Asset Management Inc Buys 789 Shares of Humana Inc. (NYSE:HUM)

CIBC Asset Management Inc boosted its stake in shares of Humana Inc. (NYSE:HUM) by 4.4% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 18,544 shares of the insurance provider’s stock after purchasing an additional 789 shares during the period. CIBC Asset Management Inc’s holdings in Humana were worth $4,705,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the stock. Sanctuary Advisors LLC lifted its position in Humana by 17.3% during the fourth quarter. Sanctuary Advisors LLC now owns 8,533 shares of the insurance provider’s stock valued at $2,165,000 after purchasing an additional 1,258 shares during the period. Pinnacle Wealth Management Advisory Group LLC lifted its position in Humana by 3.6% during the fourth quarter. Pinnacle Wealth Management Advisory Group LLC now owns 1,070 shares of the insurance provider’s stock valued at $272,000 after purchasing an additional 37 shares during the period. Manchester Capital Management LLC raised its position in Humana by 6.0% in the fourth quarter. Manchester Capital Management LLC now owns 830 shares of the insurance provider’s stock worth $211,000 after acquiring an additional 47 shares during the period. Banque Pictet & Cie SA raised its position in Humana by 114.4% in the fourth quarter. Banque Pictet & Cie SA now owns 37,541 shares of the insurance provider’s stock worth $9,525,000 after acquiring an additional 20,031 shares during the period. Finally, V Square Quantitative Management LLC raised its position in Humana by 3.8% in the fourth quarter. V Square Quantitative Management LLC now owns 2,620 shares of the insurance provider’s stock worth $665,000 after acquiring an additional 96 shares during the period. Institutional investors own 92.38% of the company’s stock.

Insider Transactions at Humana

In other news, insider Timothy S. Huval sold 3,703 shares of the business’s stock in a transaction dated Tuesday, December 31st. The shares were sold at an average price of $256.26, for a total value of $948,930.78. Following the sale, the insider now directly owns 8,181 shares in the company, valued at $2,096,463.06. The trade was a 31.16 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Insiders own 0.29% of the company’s stock.

Humana Stock Performance

Shares of NYSE HUM opened at $265.54 on Thursday. The company has a debt-to-equity ratio of 0.68, a quick ratio of 1.76 and a current ratio of 1.76. The company has a market cap of $31.97 billion, a P/E ratio of 26.69, a P/E/G ratio of 1.91 and a beta of 0.56. The firm’s fifty day moving average is $269.80 and its two-hundred day moving average is $291.28. Humana Inc. has a 52-week low of $213.31 and a 52-week high of $406.46.

Humana (NYSE:HUM) last posted its earnings results on Tuesday, February 11th. The insurance provider reported ($2.16) earnings per share for the quarter, topping analysts’ consensus estimates of ($2.26) by $0.10. Humana had a net margin of 1.02% and a return on equity of 11.70%. As a group, analysts anticipate that Humana Inc. will post 16.49 EPS for the current fiscal year.

Analyst Ratings Changes

HUM has been the topic of several recent research reports. Morgan Stanley decreased their price target on shares of Humana from $301.00 to $285.00 and set an “equal weight” rating on the stock in a research report on Wednesday, February 12th. Truist Financial increased their price target on shares of Humana from $260.00 to $290.00 and gave the stock a “hold” rating in a research report on Monday, January 6th. Piper Sandler increased their price target on shares of Humana from $270.00 to $288.00 and gave the stock a “neutral” rating in a research report on Wednesday, January 15th. TD Cowen increased their price target on shares of Humana from $261.00 to $268.00 and gave the stock a “hold” rating in a research report on Monday, November 4th. Finally, Wells Fargo & Company reduced their price objective on shares of Humana from $387.00 to $290.00 and set an “overweight” rating for the company in a research note on Monday, November 4th. Nineteen analysts have rated the stock with a hold rating and five have given a buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average target price of $285.68.

Humana Company Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.